Sponsor Dossier
Accelagen
Sponsor Dossier for Accelagen. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABURA
- Brand: AETHOXYSKLEROL
- Brand: AMBRISENTAN MSN
- Brand: APOHIDE
- Brand: ARX-FEBUXOSTAT
- Brand: ARX-SACUBITRIL/VALSARTAN
- Brand: DEFERASIROX FCT MSN
- Brand: DIMETHYL
About
Accelagen is an Australian Private Company with ABN 11142888766, registered in Victoria. The company is currently active.
Portfolio
Accelagen has 26 brands on the ARTG, of which 14 are indexable. Twelve brands have Product Information on file, three have PBAC outcomes on record, and one has an AusPAR on record. One brand is PBS-listed.
Therapeutic focus The portfolio spans the following therapeutic areas:
— Cardiology: 6 brands — Oncology: 5 brands — Neurology: 4 brands — Pain & Anaesthesia: 2 brands — Urology: 2 brands — Dermatology: 1 brand — Gastroenterology: 1 brand — Haematology: 1 brand — Immunology: 1 brand — Infectious Disease: 1 brand — Other: 1 brand — Uncategorised: 1 brand
PBS footprint
One brand in the Accelagen portfolio is PBS-listed, with the portfolio last touching the PBS schedule on 1 May 2026.
Regulatory activity
Accelagen's latest PBAC outcome was recorded on 1 November 2020, with three brands holding PBAC outcomes on record. The most recent AusPAR was published on 5 January 2016, representing one brand in the portfolio.